关键信息
-
基因名
CD42b/GP1BA
- 应用
-
别名
GP1Ba; CD42-B; CD42b-Alpha; GP1-BA; BSS; GP1B; GPIBA; Glycocalicin; Glycoprotein Ib Alpha Polypeptide, Platelet
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07359
-
表达区间
Ile19~Leu291
-
分子量
34kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CD42b, also known as glycoprotein Ib alpha (GP1BA), is a critical component of the platelet membrane receptor complex involved in hemostasis and thrombosis. Functioning as a primary receptor for von Willebrand factor (vWF), CD42b/GP1BA plays an essential role in platelet adhesion to sites of vascular injury, which is crucial for the formation of a stable blood clot. Abnormalities in this receptor can lead to bleeding disorders, such as Bernard-Soulier syndrome, characterized by impaired platelet function due to defective GP1BA expression. The recombinant protein of CD42b/GP1BA has garnered significant interest for its potential applications in both research and clinical settings. Studying this protein enhances our understanding of platelet biology and the molecular mechanisms underlying thrombosis and hemostasis. Furthermore, the recombinant form allows for the investigation of therapeutic strategies aimed at modulating platelet function in various hematological conditions. By creating a reliable source of CD42b/GP1BA, researchers can generate specific antibodies, screen for inhibitors, and develop diagnostic tools that can aid in the management of clotting disorders. Overall, the research surrounding CD42b/GP1BA recombinant protein addresses fundamental questions in vascular biology, while also offering promising avenues for therapeutic intervention in thrombotic and hemorrhagic diseases.
